SOMATOCEUTICS, LLC

Biotech · Private

SMC-101 peptide-based nanotubes for blood-brain barrier drug delivery in Alzheimer's disease

Grants
$475K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Non-toxic CNS drug delivery across the BBB in Alzheimer's and other dementias$474,531
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2018Braveheart Bio——
2019Outer Biosciences, LLC—$4.0M
2020VITAKEY, INC.—$44M
2021SOMATOCEUTICS, LLC——
2022Enveda Therapeutics, Inc.—$67M
2023Vigil Neuroscience—$195M
2024Sedare Biosciences, Inc.—$2.5M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.